{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:49:52Z","timestamp":1793386192060,"version":"4.5.0"},"reference-count":240,"publisher":"Elsevier BV","issue":"2","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.pharmthera.2013.09.004","type":"journal-article","created":{"date-parts":[[2013,9,27]],"date-time":"2013-09-27T00:49:08Z","timestamp":1380242948000},"page":"125-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":595,"title":["Targeting interleukin-6 in inflammatory autoimmune diseases and cancers"],"prefix":"10.1016","volume":"141","author":[{"given":"Xin","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Faggioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2013.09.004_bb0005","first-page":"1947","article-title":"VEGF targeting in mesotheliomas using an interleukin-6 signal inhibitor based on adenovirus gene delivery","volume":"30","author":"Adachi","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0010","doi-asserted-by":"crossref","first-page":"e37483","DOI":"10.1371\/journal.pone.0037483","article-title":"Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype","volume":"7","author":"Agusti","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0015","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/S1357-2725(97)00063-0","article-title":"IL-6-regulated transcription factors","volume":"29","author":"Akira","year":"1997","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0025","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1158\/0008-5472.2.65.1","article-title":"A spliced isoform of interleukin 6 mRNA produced by renal cell carcinoma encodes for an interleukin 6 inhibitor","volume":"65","author":"Alberti","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0020","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1038\/onc.2011.572","article-title":"Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer","volume":"31","author":"Alberti","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0030","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1084\/jem.187.4.461","article-title":"Interleukin 6 is required for the development of collagen-induced arthritis","volume":"187","author":"Alonzi","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0035","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3109\/07853890.2013.771986","article-title":"Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases","volume":"45","author":"Alten","year":"2013","journal-title":"Ann Med"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0040","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1200\/JCO.2012.44.2020","article-title":"Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia","volume":"31","author":"Ando","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0045","first-page":"932","article-title":"Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53","volume":"62","author":"Angelo","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0050","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1182\/blood.V98.10.3042","article-title":"Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus","volume":"98","author":"Aoki","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0055","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.ejca.2010.02.026","article-title":"Interleukin-6 in bone metastasis and cancer progression","volume":"46","author":"Ara","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0060","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1158\/0008-5472.CAN-12-2353","article-title":"Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma","volume":"73","author":"Ara","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0065","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s10120-005-0315-x","article-title":"Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor","volume":"8","author":"Ashizawa","year":"2005","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0070","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/(SICI)1097-0215(19990412)81:2<236::AID-IJC12>3.0.CO;2-R","article-title":"Differential regulation of IL-6 promoter activity in a human ovarian-tumor cell line transfected with various p53 mutants: involvement of AP-1","volume":"81","author":"Asschert","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0075","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.cytogfr.2012.09.001","article-title":"Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer","volume":"24","author":"Ataie-Kachoie","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0080","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/75068","article-title":"Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo","volume":"6","author":"Atreya","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0085","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1385\/CRIAI:28:3:187","article-title":"Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer","volume":"28","author":"Atreya","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0090","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/mi.2008.7","article-title":"New therapeutic strategies for treatment of inflammatory bowel disease","volume":"1","author":"Atreya","year":"2008","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0095","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1084\/jem.20111675","article-title":"B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells","volume":"209","author":"Barr","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1385\/IR:23:1:41","article-title":"IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation","volume":"23","author":"Barton","year":"2001","journal-title":"Immunol Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0105","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.V86.2.685.bloodjournal862685","article-title":"Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma","volume":"86","author":"Bataille","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0110","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1517\/14712598.2011.627850","article-title":"A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer","volume":"11","author":"Bayliss","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0115","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.4049\/jimmunol.177.5.3448","article-title":"Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells","volume":"177","author":"Bellone","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0120","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s00262-005-0047-0","article-title":"Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival","volume":"55","author":"Bellone","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0125","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3816\/CBC.2002.n.008","article-title":"Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients","volume":"2","author":"Benoy","year":"2002","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0130","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/(SICI)1097-0215(19970729)72:3<424::AID-IJC9>3.0.CO;2-R","article-title":"Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma","volume":"72","author":"Blay","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0135","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<134::AID-CNCR19>3.0.CO;2-C","article-title":"Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity","volume":"85","author":"Borsellino","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0140","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1126\/science.1083901","article-title":"Hexameric structure and assembly of the interleukin-6\/IL-6 alpha-receptor\/gp130 complex","volume":"300","author":"Boulanger","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0145","doi-asserted-by":"crossref","first-page":"7102","DOI":"10.4049\/jimmunol.180.11.7102","article-title":"Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells","volume":"180","author":"Briso","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0150","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/ard.2010.139725","article-title":"Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)","volume":"70","author":"Burmester","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0155","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1365-2249.2006.03212.x","article-title":"Interleukin-6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte-dendritic cell cross-talk","volume":"146","author":"Cabillic","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0160","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/039463200702000105","article-title":"Interleukin-6, interleukin-10 and heat shock protein-90 expression in renal epithelial neoplasias and surrounding normal-appearing renal parenchyma","volume":"20","author":"Cardillo","year":"2007","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0165","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3899\/jrheum.090194","article-title":"Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus","volume":"37","author":"Cash","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0170","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1038\/sj.onc.1210097","article-title":"The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1","volume":"26","author":"Cavarretta","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0175","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1164\/rccm.201110-1792OC","article-title":"Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease","volume":"185","author":"Celli","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0180","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.3899\/jrheum.120506","article-title":"Influence of the IL6 gene in susceptibility to systemic sclerosis","volume":"39","author":"Cenit","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0185","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1182\/blood-2007-01-067918","article-title":"Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils","volume":"110","author":"Chalaris","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0190","first-page":"4195","article-title":"Cytokine production in primary histoculture by human normal kidney, renal cell carcinoma and benign renal angiomyolipoma tissues","volume":"18","author":"Chang","year":"1998","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0195","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.clml.2012.12.010","article-title":"Complete remission achieved with single agent CNTO 328, an anti-IL-6 monoclonal antibody, in relapsed and refractory myeloma","volume":"13","author":"Chari","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0200","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1186\/bcr1648","article-title":"Oestrogen receptor negative breast cancers exhibit high cytokine content","volume":"9","author":"Chavey","year":"2007","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0205","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1476-4598-12-26","article-title":"IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus","volume":"12","author":"Chen","year":"2013","journal-title":"Mol Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0215","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.smim.2007.10.015","article-title":"Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation","volume":"19","author":"Chen","year":"2007","journal-title":"Semin Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0210","doi-asserted-by":"crossref","first-page":"e61901","DOI":"10.1371\/journal.pone.0061901","article-title":"IL-6 expression regulates tumorigenicity and correlates with prognosis in bladder cancer","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0220","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.4049\/jimmunol.1203032","article-title":"Cutting edge: STAT1 is required for IL-6-mediated Bcl6 induction for early follicular helper cell differentiation","volume":"190","author":"Choi","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0225","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/jso.10269","article-title":"Serum interleukin-6 levels reflect the disease status of colorectal cancer","volume":"83","author":"Chung","year":"2003","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0230","first-page":"8851","article-title":"Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells","volume":"61","author":"Conze","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0235","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1158\/1078-0432.CCR-11-0945","article-title":"Interleukin-6 as a therapeutic target in human ovarian cancer","volume":"17","author":"Coward","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0240","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1182\/blood-2003-08-2860","article-title":"IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma","volume":"103","author":"Cozen","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0245","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/jcb.20477","article-title":"Interleukin-6 regulation of prostate cancer cell growth","volume":"95","author":"Culig","year":"2005","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0250","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood.V95.8.2630","article-title":"Vascular endothelial growth factor and interleukin-6 in paracrine tumor\u2013stromal cell interactions in multiple myeloma","volume":"95","author":"Dankbar","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0255","first-page":"1403","article-title":"Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis","volume":"24","author":"De Benedetti","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0260","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/blood.V100.1.194","article-title":"Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells","volume":"100","author":"Derenne","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0265","first-page":"1510","article-title":"Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid","volume":"24","author":"Desgeorges","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0270","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1074-7613(00)00078-9","article-title":"Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1","volume":"13","author":"Diehl","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0275","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0161-5890(02)00210-9","article-title":"The two faces of IL-6 on Th1\/Th2 differentiation","volume":"39","author":"Diehl","year":"2002","journal-title":"Mol Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0280","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/icb.2012.17","article-title":"IL-6 triggers IL-21 production by human CD4+ T cells to drive STAT3-dependent plasma cell differentiation in B cells","volume":"90","author":"Diehl","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0285","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1084\/jem.20081571","article-title":"The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells","volume":"206","author":"Dienz","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0290","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/02770900600859123","article-title":"Effect of obesity on clinical presentation and response to treatment in asthma","volume":"43","author":"Dixon","year":"2006","journal-title":"J Asthma"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0295","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1158\/1078-0432.CCR-09-3122","article-title":"Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer","volume":"16","author":"Dorff","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0300","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2011-201282","article-title":"Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)","volume":"72","author":"Dougados","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0305","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1158\/1078-0432.CCR-06-0861","article-title":"Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer","volume":"12","author":"Duan","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0310","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/1523-1747.ep12483971","article-title":"Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6","volume":"97","author":"Duncan","year":"1991","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0315","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1002\/cncr.20672","article-title":"Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis","volume":"101","author":"Ebrahimi","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0320","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2011-12-400051","article-title":"Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia","volume":"119","author":"Eghtedar","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0325","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0961203310392432","article-title":"Interleukin-6 promotes arthritis and joint deformation in patients with systemic lupus erythematosus","volume":"20","author":"Eilertsen","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0330","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.bbrc.2004.08.196","article-title":"Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist","volume":"323","author":"Enomoto","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0335","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaci.2013.01.057","article-title":"A functional IL-6 receptor (IL6R) variant is a risk factor for persistent atopic dermatitis","volume":"132","author":"Esparza-Gordillo","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0340","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood.V97.1.256","article-title":"Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome","volume":"97","author":"Fayad","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0345","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0140-6736(11)60874-X","article-title":"Identification of IL6R and chromosome 11q13.5 as risk loci for asthma","volume":"378","author":"Ferreira","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0350","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.4049\/jimmunol.181.3.2189","article-title":"IL-6 regulates neutrophil trafficking during acute inflammation via STAT3","volume":"181","author":"Fielding","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0355","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/intimm\/dxm037","article-title":"Local blockade of IL-6R signaling induces lung CD4+ T cell apoptosis in a murine model of asthma via regulatory T cells","volume":"19","author":"Finotto","year":"2007","journal-title":"Int Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0360","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejca.2011.10.014","article-title":"Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone\/prednisone versus mitoxantrone\/prednisone alone in metastatic castration-resistant prostate cancer","volume":"48","author":"Fizazi","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0365","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/sj.onc.1208437","article-title":"A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells","volume":"24","author":"Flowers","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0370","doi-asserted-by":"crossref","first-page":"7144","DOI":"10.1158\/1078-0432.CCR-09-1483","article-title":"A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma","volume":"15","author":"Fulciniti","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0375","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0380","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0385","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1172\/JCI31871","article-title":"Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas","volume":"117","author":"Gao","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0390","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ygyno.2006.08.043","article-title":"Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma","volume":"103","author":"Garg","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0395","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature09447","article-title":"Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling","volume":"467","author":"Ghoreschi","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0400","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/eji.1830200134","article-title":"Interleukin 6 production in the central nervous system during experimental autoimmune encephalomyelitis","volume":"20","author":"Gijbels","year":"1990","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0405","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/S0002-9440(10)63067-2","article-title":"Interleukin-6 is an autocrine growth factor in human prostate cancer","volume":"159","author":"Giri","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0410","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.cell.2010.02.016","article-title":"Mechanisms underlying inflammation in neurodegeneration","volume":"140","author":"Glass","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0415","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ccr.2007.12.020","article-title":"Autocrine IL-6 signaling: a key event in tumorigenesis?","volume":"13","author":"Grivennikov","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0420","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1158\/1078-0432.CCR-10-1095","article-title":"Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer","volume":"16","author":"Guo","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0425","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1158\/0008-5472.CAN-12-4524-T","article-title":"Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8","volume":"73","author":"Hartman","year":"2013","journal-title":"Cancer Res"},{"issue":"510\u2013515","key":"10.1016\/j.pharmthera.2013.09.004_bb0430","first-page":"e511","article-title":"The IL6R variation Asp(358)Ala is a potential modifier of lung function in subjects with asthma","volume":"130","author":"Hawkins","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0435","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/thx.2008.111278","article-title":"Associations of IL6 polymorphisms with lung function decline and COPD","volume":"64","author":"He","year":"2009","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj20030407","article-title":"Principles of interleukin (IL)-6-type cytokine signalling and its regulation","volume":"374","author":"Heinrich","year":"2003","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0445","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1042\/bj2650621","article-title":"Interleukin-6 and the acute phase response","volume":"265","author":"Heinrich","year":"1990","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0450","doi-asserted-by":"crossref","first-page":"8386","DOI":"10.1038\/sj.onc.1207170","article-title":"Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma","volume":"22","author":"Hideshima","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0455","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0460","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2567.2007.02649.x","article-title":"Interleukin-6 is responsible for aberrant B-cell receptor-mediated regulation of RAG expression in systemic lupus erythematosus","volume":"122","author":"Hillion","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0465","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/art.1780330506","article-title":"Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement","volume":"33","author":"Hirohata","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0470","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/CMR.0b013e3283550aa5","article-title":"Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma","volume":"22","author":"Hoejberg","year":"2012","journal-title":"Melanoma Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0475","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/CMR.0b013e3283543d72","article-title":"Interleukin-6 and melanoma","volume":"22","author":"Hoejberg","year":"2012","journal-title":"Melanoma Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0480","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/ijc.1388","article-title":"The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells","volume":"93","author":"Honemann","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0485","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1002\/cncr.22999","article-title":"Interleukin-6 and its receptor in cancer: implications for translational therapeutics","volume":"110","author":"Hong","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0490","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1046\/j.1440-1746.1999.01989.x","article-title":"Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease","volume":"14","author":"Hosokawa","year":"1999","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0495","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s10637-012-9857-z","article-title":"A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer","volume":"31","author":"Hudes","year":"2013","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0500","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2141.2010.08533.x","article-title":"Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma","volume":"152","author":"Hunsucker","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0505","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/sj.bjc.6601545","article-title":"The -174G\/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype","volume":"90","author":"Iacopetta","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0510","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.27221","article-title":"Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study","volume":"62","author":"Illei","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0515","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1517\/14728222.8.4.287","article-title":"Novel therapy for Crohn's disease targeting IL-6 signalling","volume":"8","author":"Ito","year":"2004","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0520","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1053\/j.gastro.2004.01.012","article-title":"A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease","volume":"126","author":"Ito","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0525","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1074-7613(03)00208-5","article-title":"Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6","volume":"19","author":"Jego","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0535","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/jir.2005.25.241","article-title":"IL-6 transsignaling: the in vivo consequences","volume":"25","author":"Jones","year":"2005","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0530","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study","volume":"69","author":"Jones","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0540","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1046\/j.1432-1327.2001.01867.x","article-title":"Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses","volume":"268","author":"Jostock","year":"2001","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0545","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/pros.21362","article-title":"The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study","volume":"71","author":"Karkera","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0550","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1006\/cyto.2002.2012","article-title":"Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice","volume":"20","author":"Katsume","year":"2002","journal-title":"Cytokine"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0555","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1006\/cyto.1997.0343","article-title":"A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis","volume":"10","author":"Keul","year":"1998","journal-title":"Cytokine"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0560","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cellsig.2013.01.007","article-title":"Role of the IL-6\u2013JAK1\u2013STAT3\u2013Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells","volume":"25","author":"Kim","year":"2013","journal-title":"Cell Signal"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0565","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur J Immunol"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2013.09.004_bb0570","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar1916","article-title":"Interleukin-6: discovery of a pleiotropic cytokine","volume":"8","author":"Kishimoto","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0575","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/intimm\/dxq030","article-title":"IL-6: from its discovery to clinical applications","volume":"22","author":"Kishimoto","year":"2010","journal-title":"Int Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0580","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1126\/science.1411569","article-title":"Interleukin-6 and its receptor: a paradigm for cytokines","volume":"258","author":"Kishimoto","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0585","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ajpath.2011.09.013","article-title":"Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma","volume":"180","author":"Kitaba","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0590","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00384-009-0818-8","article-title":"Serum interleukin-6 levels in colorectal cancer patients\u2013a summary of published results","volume":"25","author":"Knupfer","year":"2010","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0595","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.molcel.2012.06.014","article-title":"Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population","volume":"47","author":"Korkaya","year":"2012","journal-title":"Mol Cell"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0600","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.30158","volume":"63","author":"Kremer","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0605","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3171\/2008.12.JNS081284","article-title":"Antitumor effect of humanized anti-interleukin-6 receptor antibody (tocilizumab) on glioma cell proliferation. Laboratory investigation","volume":"111","author":"Kudo","year":"2009","journal-title":"J Neurosurg"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0610","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.urology.2006.09.039","article-title":"Interleukin 6 is associated with cachexia in patients with prostate cancer","volume":"69","author":"Kuroda","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0615","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1158\/1078-0432.CCR-12-3349","article-title":"A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease","volume":"19","author":"Kurzrock","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0620","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1046\/j.1365-2141.1996.4721018.x","article-title":"Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma","volume":"93","author":"Kyrtsonis","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0625","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.cyto.2012.12.025","article-title":"Alternative splicing and proteolytic rupture contribute to the generation of soluble IL-6 receptors (sIL-6R) in rheumatoid arthritis","volume":"61","author":"Lamas","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0630","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1002\/cncr.11072","article-title":"A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications","volume":"97","author":"Lauta","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0635","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/0961203311422711","article-title":"The association between interleukin-6 polymorphisms and systemic lupus erythematosus: a meta-analysis","volume":"21","author":"Lee","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0640","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1365-2249.2009.03916.x","article-title":"An inhibitor of interleukin-6 trans-signalling, sgp130, contributes to impaired acute phase response in human chronic liver disease","volume":"156","author":"Lemmers","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0645","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/bcr2725","article-title":"Differential interleukin-6\/Stat3 signaling as a function of cellular context mediates Ras-induced transformation","volume":"12","author":"Leslie","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0650","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/gut.2009.184176","article-title":"Disease-related expression of the IL6\/STAT3\/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis","volume":"59","author":"Li","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0655","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2567.2006.02433.x","article-title":"Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus","volume":"119","author":"Liang","year":"2006","journal-title":"Immunology"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0660","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4049\/jimmunol.147.1.117","article-title":"Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis","volume":"147","author":"Linker-Israeli","year":"1991","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0665","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/ijc.20871","article-title":"Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1","volume":"115","author":"Loeffler","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0670","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1056\/NEJMoa032520","article-title":"Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes","volume":"350","author":"Lossos","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0675","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/978-1-4613-1241-3_8","article-title":"Interleukin-6: a comprehensive review","volume":"80","author":"Lotz","year":"1995","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0680","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0165-5728(91)90073-G","article-title":"Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis","volume":"32","author":"Maimone","year":"1991","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0685","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3109\/08916934.2012.665523","article-title":"Pathogenic and regulatory roles for B cells in experimental autoimmune encephalomyelitis","volume":"45","author":"Mann","year":"2012","journal-title":"Autoimmunity"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0690","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1038\/sj.bjc.6602248","article-title":"The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer","volume":"91","author":"McKeown","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0695","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.4049\/jimmunol.172.9.5676","article-title":"Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms","volume":"172","author":"McLoughlin","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0700","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/annrheumdis-2011-200704","article-title":"A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate","volume":"71","author":"Mease","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0705","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s12079-012-0185-z","article-title":"TLR3 activation evokes IL-6 secretion, autocrine regulation of Stat3 signaling and TLR2 expression in human bronchial epithelial cells","volume":"7","author":"Melkamu","year":"2013","journal-title":"J Cell Commun Signal"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0710","doi-asserted-by":"crossref","first-page":"8256","DOI":"10.1074\/jbc.M607712200","article-title":"The MicroRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes","volume":"282","author":"Meng","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0715","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.intimp.2005.05.010","article-title":"Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family","volume":"5","author":"Mihara","year":"2005","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0720","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1046\/j.1365-2249.1998.00612.x","article-title":"IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB\/WF1 mice","volume":"112","author":"Mihara","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0725","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1023\/B:DDAS.0000034556.48527.6e","article-title":"C-reactive protein as a prognostic variable that reflects uncontrolled up-regulation of the IL-1-IL-6 network system in colorectal carcinoma","volume":"49","author":"Miki","year":"2004","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0730","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1038\/bjc.2013.174","article-title":"Serum levels of IL-6 and IL-1beta can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer","volume":"108","author":"Mitsunaga","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0735","doi-asserted-by":"crossref","first-page":"S437","DOI":"10.1016\/S0091-6749(99)70159-4","article-title":"IL-6 synthesis by rheumatoid synoviocytes is autonomously upregulated at the transcriptional level","volume":"103","author":"Miyazawa","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0740","first-page":"590","article-title":"Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody","volume":"55","author":"Mizutani","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0745","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1046\/j.1365-2141.2000.02093.x","article-title":"A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma","volume":"109","author":"Moreau","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0750","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/13684730210002328","article-title":"Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study","volume":"7","author":"Mouawad","year":"2002","journal-title":"Cytokines Cell Mol Ther"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0755","first-page":"335","article-title":"An unexpected inverse correlation between soluble epidermal growth factor receptor and interleukin-6 in metastatic malignant melanoma patients","volume":"16","author":"Mouawad","year":"2006","journal-title":"Melanoma Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0760","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3899\/jrheum.111423","article-title":"Interleukin 6 in systemic sclerosis and potential implications for targeted therapy","volume":"39","author":"Muangchan","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0765","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.4049\/jimmunol.152.10.4958","article-title":"The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site","volume":"152","author":"Mullberg","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0770","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.11143","article-title":"Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis","volume":"48","author":"Nakahara","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0775","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/annrheumdis-2012-202768","article-title":"Suppression of elevations in serum C reactive protein levels by anti-IL-6 autoantibodies in two patients with severe bacterial infections","volume":"72","author":"Nanki","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0780","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.V82.4.1120.1120","article-title":"Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130","volume":"82","author":"Narazaki","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0785","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.molmed.2007.12.007","article-title":"The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer","volume":"14","author":"Naugler","year":"2008","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0790","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1200\/JCO.2004.06.121","article-title":"Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6\u2013from the Groupe Francais d'Immunotherapie","volume":"22","author":"Negrier","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0795","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cytogfr.2011.02.003","article-title":"IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer","volume":"22","author":"Neurath","year":"2011","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0800","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.4049\/jimmunol.0802923","article-title":"IL-6 is required for airway mucus production induced by inhaled fungal allergens","volume":"183","author":"Neveu","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0805","doi-asserted-by":"crossref","first-page":"10794","DOI":"10.1158\/0008-5472.CAN-05-0623","article-title":"Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine","volume":"65","author":"Nilsson","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0810","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease","volume":"106","author":"Nishimoto","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0815","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood.V95.1.56","article-title":"Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy","volume":"95","author":"Nishimoto","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0820","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0830","doi-asserted-by":"crossref","first-page":"946048","DOI":"10.1155\/2012\/946048","article-title":"Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions","volume":"2012","author":"Ogata","year":"2012","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0835","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jjco\/28.1.12","article-title":"Elevated serum interleukin-6 levels in patients with pancreatic cancer","volume":"28","author":"Okada","year":"1998","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0825","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cytogfr.2012.04.003","article-title":"Interleukin-6, its role in fibrosing conditions","volume":"23","author":"O'Reilly","year":"2012","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0840","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.4049\/jimmunol.169.6.3353","article-title":"IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae","volume":"169","author":"Palmqvist","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0845","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.coi.2010.01.021","article-title":"Myeloid-derived suppressor cell heterogeneity and subset definition","volume":"22","author":"Peranzoni","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0850","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrc1256","article-title":"Tumour-educated macrophages promote tumour progression and metastasis","volume":"4","author":"Pollard","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0855","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/pros.20057","article-title":"Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells","volume":"60","author":"Pu","year":"2004","journal-title":"Prostate"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0860","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s10637-010-9429-z","article-title":"Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor","volume":"29","author":"Quintas-Cardama","year":"2010","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0865","first-page":"267","article-title":"Regulation of ovarian carcinoma SKOV-3 cell proliferation and secretion of MMPs by autocrine IL-6","volume":"27","author":"Rabinovich","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0870","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1477-7819-9-18","article-title":"Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients","volume":"9","author":"Ravishankaran","year":"2011","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0875","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nrrheum.2011.37","article-title":"C-reactive protein in rheumatology: biology and genetics","volume":"7","author":"Rhodes","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0880","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.it.2012.07.003","article-title":"Interleukin-6: from an inflammatory marker to a target for inflammatory diseases","volume":"33","author":"Rincon","year":"2012","journal-title":"Trends Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0885","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.7150\/ijbs.4874","article-title":"Role of IL-6 in asthma and other inflammatory pulmonary diseases","volume":"8","author":"Rincon","year":"2012","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0890","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1189\/jlb.1105674","article-title":"Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer","volume":"80","author":"Rose-John","year":"2006","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0895","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.bmt.1705138","article-title":"Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140mg\/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects","volume":"36","author":"Rossi","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0900","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/sj.bjc.6605872","article-title":"A phase I\/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer","volume":"103","author":"Rossi","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0905","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2407-7-35","article-title":"Growth regulation of simian and human AIDS-related non-Hodgkin's lymphoma cell lines by TGF-beta1 and IL-6","volume":"7","author":"Ruff","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0910","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0140-6736(00)04239-2","article-title":"Systemic lupus erythematosus","volume":"357","author":"Ruiz-Irastorza","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0915","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/ijc.10833","article-title":"Circulating interleukin-6 predicts survival in patients with metastatic breast cancer","volume":"103","author":"Salgado","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0920","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.34477","article-title":"Brief report: inhibition of interleukin-6 function corrects Th17\/Treg cell imbalance in patients with rheumatoid arthritis","volume":"64","author":"Samson","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0925","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.cyto.2012.12.023","article-title":"Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels","volume":"61","author":"Sanchez-Correa","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0930","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1172\/JCI32533","article-title":"IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland","volume":"117","author":"Sansone","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0935","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1677\/ERC-09-0200","article-title":"Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells","volume":"17","author":"Santer","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0940","first-page":"851","article-title":"Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth","volume":"53","author":"Sato","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0945","doi-asserted-by":"crossref","first-page":"170ra115","DOI":"10.1126\/scitranslmed.3004970","article-title":"In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling","volume":"5","author":"Schneider","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0950","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/bjc.1996.294","article-title":"The relationship between weight loss and interleukin 6 in non-small-cell lung cancer","volume":"73","author":"Scott","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0955","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/1535-7163.MCT-11-0951","article-title":"Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancer","volume":"11","author":"Seavey","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0960","doi-asserted-by":"crossref","first-page":"9041","DOI":"10.1073\/pnas.0802218105","article-title":"IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis","volume":"105","author":"Serada","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0965","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1093\/rheumatology\/keq275","article-title":"The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab","volume":"49","author":"Shima","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0970","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1159\/000350836","article-title":"In patients with colorectal cancer, preoperative serum interleukin-6 level and granulocyte\/lymphocyte ratio are clinically relevant biomarkers of long-term cancer progression","volume":"84","author":"Shimazaki","year":"2013","journal-title":"Oncology"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0975","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-09-0287","article-title":"Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma","volume":"15","author":"Shinriki","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0980","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/path.2935","article-title":"Interleukin-6 signalling regulates vascular endothelial growth factor-C synthesis and lymphangiogenesis in human oral squamous cell carcinoma","volume":"225","author":"Shinriki","year":"2011","journal-title":"J Pathol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0985","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/annrheumdis-2012-201310","article-title":"Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus","volume":"72","author":"Shirota","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0990","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s10552-007-9049-x","article-title":"IL6 genotypes and colon and rectal cancer","volume":"18","author":"Slattery","year":"2007","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb0995","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2370.2004.00462.x","article-title":"Cytokine gene polymorphisms and breast cancer susceptibility and prognosis","volume":"31","author":"Smith","year":"2004","journal-title":"Eur J Immunogenet"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1000","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","article-title":"New therapies for treatment of rheumatoid arthritis","volume":"370","author":"Smolen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1005","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1010","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/ajh.2830390303","article-title":"Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma","volume":"39","author":"Solary","year":"1992","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1015","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1158\/1535-7163.MCT-10-0502","article-title":"JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1\u2013STAT3 signaling","volume":"10","author":"Song","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1020","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/ng.582","article-title":"Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci","volume":"42","author":"Stahl","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1025","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/pros.20492","article-title":"Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328","volume":"66","author":"Steiner","year":"2006","journal-title":"Prostate"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1030","first-page":"67","article-title":"Overexpression of Interleukin-6 suppresses cisplatin-induced cytotoxicity in esophageal squamous cell carcinoma cells","volume":"31","author":"Suchi","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1035","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1002\/1529-0131(199812)41:12<2117::AID-ART6>3.0.CO;2-P","article-title":"Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis","volume":"41","author":"Takagi","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1040","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2217\/imt.11.147","article-title":"Immunotherapeutic implication of IL-6 blockade","volume":"4","author":"Tanaka","year":"2012","journal-title":"Immunotherapy"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1045","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1016\/j.febslet.2011.03.023","article-title":"Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases","volume":"585","author":"Tanaka","year":"2011","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1050","first-page":"460","article-title":"Interleukin-1alpha, 6 regulate the secretion of vascular endothelial growth factor A, C in pancreatic cancer","volume":"4","author":"Tang","year":"2005","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1055","first-page":"867","article-title":"The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells","volume":"21","author":"Tassone","year":"2002","journal-title":"Int J Oncol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1060","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/sj.bjc.6603586","article-title":"Interleukin-6 gene amplification and shortened survival in glioblastoma patients","volume":"96","author":"Tchirkov","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1065","article-title":"Anemia in diffuse large B cell non-Hodgkin lymphoma: the role of IL-6, hepcidin and erythropoietin","author":"Tisi","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1070","first-page":"4653","article-title":"Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence","volume":"9","author":"Trikha","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1075","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1006\/cyto.1995.0047","article-title":"Nonsteroidal anti-inflammatory drugs differentially regulate cytokine production in human lymphocytes: up-regulation of TNF, IFN-gamma and IL-2, in contrast to down-regulation of IL-6 production","volume":"7","author":"Tsuboi","year":"1995","journal-title":"Cytokine"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1080","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1200\/JCO.2009.27.2377","article-title":"Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease","volume":"28","author":"van Rhee","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1085","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cyto.2013.02.029","article-title":"High serum levels of HIF-1alpha in psoriatic patients correlate with an over-expression of IL-6","volume":"62","author":"Vasilopoulos","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1090","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.immuni.2006.01.001","article-title":"TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells","volume":"24","author":"Veldhoen","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1095","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1158\/1078-0432.CCR-07-1293","article-title":"Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma","volume":"13","author":"Voorhees","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1100","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2141.2009.07647.x","article-title":"Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death","volume":"145","author":"Voorhees","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1105","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bjh.12266","article-title":"A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma","volume":"161","author":"Voorhees","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1110","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/eji.1830201112","article-title":"Glucocorticoids inhibit the production of IL6 from monocytes, endothelial cells and fibroblasts","volume":"20","author":"Waage","year":"1990","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1115","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/0008-5472.CAN-05-3447","article-title":"Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice","volume":"66","author":"Wallner","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1120","first-page":"6959","article-title":"Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures","volume":"50","author":"Watson","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1125","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0022-5347(01)67735-8","article-title":"Hypercalcemia and cosecretion of interleukin-6 and parathyroid hormone related peptide by a human renal cell carcinoma implanted into nude mice","volume":"153","author":"Weissglas","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1130","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1365-2125.2011.03964.x","article-title":"Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study","volume":"72","author":"Xu","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1135","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.4049\/jimmunol.164.9.4878","article-title":"IL-6 is required for the development of Th1 cell-mediated murine colitis","volume":"164","author":"Yamamoto","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1140","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1471-2350-10-23","article-title":"IL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: a case-control study","volume":"10","author":"Yanbaeva","year":"2009","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1145","doi-asserted-by":"crossref","first-page":"15535","DOI":"10.1073\/pnas.1009472107","article-title":"TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer","volume":"107","author":"Yao","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1150","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1155","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1586\/eci.10.41","article-title":"Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis","volume":"6","author":"Yokota","year":"2010","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1160","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1164\/ajrccm.151.5.7735584","article-title":"Circulating interleukin-6 levels in patients with bronchial asthma","volume":"151","author":"Yokoyama","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1165","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/sj.bjc.6600257","article-title":"Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma","volume":"86","author":"Yoshida","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1170","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1158\/0008-5472.CAN-06-3641","article-title":"Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor","volume":"67","author":"Yoshio-Hoshino","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1175","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood.V74.4.1360.1360","article-title":"Pathogenic significance of interleukin-6 (IL-6\/BSF-2) in Castleman's disease","volume":"74","author":"Yoshizaki","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1185","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1180","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/0008-5472.CAN-12-3840","article-title":"miR145 targets the SOX9\/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer","volume":"73","author":"Yu","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1195","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s10875-012-9840-7","article-title":"MicroRNA let-7a ameliorates con A-induced hepatitis by inhibiting IL-6-dependent Th17 cell differentiation","volume":"33","author":"Zhang","year":"2013","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1190","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1074\/jbc.M112.351197","article-title":"A newly identified microRNA, mmu-miR-7578, functions as a negative regulator on inflammatory cytokines tumor necrosis factor-alpha and interleukin-6 via targeting Egr1 in vivo","volume":"288","author":"Zhang","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.09.004_bb1200","doi-asserted-by":"crossref","first-page":"187","DOI":"10.5414\/CP201785","article-title":"Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjects","volume":"51","author":"Zhuang","year":"2013","journal-title":"Int J Clin Pharmacol Ther"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725813001939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725813001939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T17:22:47Z","timestamp":1688491367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725813001939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":240,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0163725813001939"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2013.09.004","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting interleukin-6 in inflammatory autoimmune diseases and cancers","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2013.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}